blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability
Register Forum

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
FAQ - Register Alert
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP3038652

EP3038652 - COMBINATION OF AN ALK INHIBITOR AND A CDK INHIBITOR FOR THE TREATMENT OF CELL PROLIFERATIVE DISEASES [Right-click to bookmark this link]
StatusNo opposition filed within time limit
Status updated on  25.01.2019
Database last updated on 03.09.2024
FormerThe patent has been granted
Status updated on  16.02.2018
FormerGrant of patent is intended
Status updated on  16.10.2017
FormerRequest for examination was made
Status updated on  19.09.2017
FormerGrant of patent is intended
Status updated on  25.04.2017
Most recent event   Tooltip10.07.2020Lapse of the patent in a contracting state
New state(s): IS		published on 12.08.2020  [2020/33]
Applicant(s)For all designated states
Novartis AG
Lichtstrasse 35
4056 Basel / CH
[2016/27]
Inventor(s)01 / HARRIS, Jennifer Leslie
Novartis Institute for Functional Genomics Inc.
dba Genomics Institute of the Novartis Research
Foundation
10675 John Jay Hopkins Drive
San Diego, California 92121 / US
02 / LI, Nanxin
Novartis Insitute for Functional Genomics Inc.
dba Genomics Institute of the Novartis Research
Foundation
10675 John Jay Hopkins Drive
San Diego, California 92121 / US
03 / SMITH, Timothy R.
Novartis Institute for Functional Genomics Inc.
dba Genomics Institute of theNovartis Research
Foundation
10675 John Jay Hopkins Drive
San Diego, California 92121 / US
 [2016/27]
Representative(s)Kristl, Jernej, et al
Novartis Pharma AG
IP Patent Department
Forum 1
Novartis Campus
4056 Basel / CH
[2016/27]
Application number, filing date14766301.728.08.2014
[2016/27]
WO2014US53244
Priority number, dateUS201361871275P28.08.2013         Original published format: US 201361871275 P
[2016/27]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2015031666
Date:05.03.2015
Language:EN
[2015/09]
Type: A1 Application with search report 
No.:EP3038652
Date:06.07.2016
Language:EN
The application published by WIPO in one of the EPO official languages on 05.03.2015 takes the place of the publication of the European patent application.
[2016/27]
Type: B1 Patent specification 
No.:EP3038652
Date:21.03.2018
Language:EN
[2018/12]
Search report(s)International search report - published on:EP05.03.2015
ClassificationIPC:A61K31/506, A61K31/519, A61K45/06, A61P35/00
[2017/19]
CPC:
A61K31/519 (EP,KR,US); A61K31/506 (EP,KR,US); A61K45/06 (EP,KR,US);
A61P25/00 (EP); A61P35/00 (EP); A61P43/00 (EP);
A61K2300/00 (KR) (-)
C-Set:
A61K31/506, A61K2300/00 (EP,US);
A61K31/519, A61K2300/00 (US,EP)
Former IPC [2016/27]A61K45/00, A61K31/506, A61K31/519, A61P35/00
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2016/27]
Extension statesBA29.03.2016
ME29.03.2016
TitleGerman:KOMBINATION VON ALK- UND CDK-HEMMERN ZUR BEHANDLUNG ZELLPROLIFERATIVER ERKRANKUNGEN[2017/19]
English:COMBINATION OF AN ALK INHIBITOR AND A CDK INHIBITOR FOR THE TREATMENT OF CELL PROLIFERATIVE DISEASES[2016/27]
French:COMBINAISON D'UN INHIBITEUR D'ALK ET D'UN INHIBITEUR DE CDK POUR LE TRAITEMENT DE MALADIES PROLIFÉRATIVES CELLULAIRES[2017/19]
Former [2016/27]KOMBINATION EINES ALK-INHIBITORS UND CDK-INHIBITORS ZUR BEHANDLUNG VON ZELLPROLIFERATIVEN ERKRANKUNGEN
Former [2016/27]COMBINAISON D'UN INHIBITEUR D'ALK ET D'UN INHIBITEUR DE CDK POUR LE TRAITEMENT DE MALADIES CELLULAIRES PROLIFÉRATIVES
Entry into regional phase29.03.2016National basic fee paid 
29.03.2016Designation fee(s) paid 
29.03.2016Examination fee paid 
Examination procedure26.06.2015Request for preliminary examination filed
International Preliminary Examining Authority: EP
29.03.2016Examination requested  [2016/27]
17.10.2016Amendment by applicant (claims and/or description)
26.04.2017Communication of intention to grant the patent
05.09.2017Disapproval of the communication of intention to grant the patent by the applicant or resumption of examination proceedings by the EPO
06.09.2017Fee for grant paid
06.09.2017Fee for publishing/printing paid
17.10.2017Communication of intention to grant the patent
07.02.2018Receipt of the translation of the claim(s)
Opposition(s)02.01.2019No opposition filed within time limit [2019/09]
Fees paidRenewal fee
11.08.2016Renewal fee patent year 03
14.08.2017Renewal fee patent year 04
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipHU28.08.2014
AL21.03.2018
AT21.03.2018
CY21.03.2018
CZ21.03.2018
DK21.03.2018
EE21.03.2018
FI21.03.2018
HR21.03.2018
LT21.03.2018
LV21.03.2018
MC21.03.2018
MK21.03.2018
NL21.03.2018
PL21.03.2018
RO21.03.2018
RS21.03.2018
SE21.03.2018
SI21.03.2018
SK21.03.2018
SM21.03.2018
TR21.03.2018
BG21.06.2018
NO21.06.2018
GR22.06.2018
IS21.07.2018
PT23.07.2018
IE28.08.2018
LU28.08.2018
MT28.08.2018
BE31.08.2018
CH31.08.2018
LI31.08.2018
[2020/33]
Former [2020/31]HU28.08.2014
AL21.03.2018
AT21.03.2018
CY21.03.2018
CZ21.03.2018
DK21.03.2018
EE21.03.2018
FI21.03.2018
HR21.03.2018
LT21.03.2018
LV21.03.2018
MC21.03.2018
MK21.03.2018
NL21.03.2018
PL21.03.2018
RO21.03.2018
RS21.03.2018
SE21.03.2018
SI21.03.2018
SK21.03.2018
SM21.03.2018
TR21.03.2018
BG21.06.2018
NO21.06.2018
GR22.06.2018
PT23.07.2018
IE28.08.2018
LU28.08.2018
MT28.08.2018
BE31.08.2018
CH31.08.2018
LI31.08.2018
Former [2020/30]HU28.08.2014
AL21.03.2018
AT21.03.2018
CY21.03.2018
CZ21.03.2018
DK21.03.2018
EE21.03.2018
FI21.03.2018
HR21.03.2018
LT21.03.2018
LV21.03.2018
MC21.03.2018
NL21.03.2018
PL21.03.2018
RO21.03.2018
RS21.03.2018
SE21.03.2018
SI21.03.2018
SK21.03.2018
SM21.03.2018
TR21.03.2018
BG21.06.2018
NO21.06.2018
GR22.06.2018
PT23.07.2018
IE28.08.2018
LU28.08.2018
MT28.08.2018
BE31.08.2018
CH31.08.2018
LI31.08.2018
Former [2020/16]AL21.03.2018
AT21.03.2018
CY21.03.2018
CZ21.03.2018
DK21.03.2018
EE21.03.2018
FI21.03.2018
HR21.03.2018
LT21.03.2018
LV21.03.2018
MC21.03.2018
NL21.03.2018
PL21.03.2018
RO21.03.2018
RS21.03.2018
SE21.03.2018
SI21.03.2018
SK21.03.2018
SM21.03.2018
TR21.03.2018
BG21.06.2018
NO21.06.2018
GR22.06.2018
PT23.07.2018
LU28.08.2018
MT28.08.2018
BE31.08.2018
CH31.08.2018
LI31.08.2018
Former [2020/08]AL21.03.2018
AT21.03.2018
CY21.03.2018
CZ21.03.2018
DK21.03.2018
EE21.03.2018
FI21.03.2018
HR21.03.2018
LT21.03.2018
LV21.03.2018
MC21.03.2018
NL21.03.2018
PL21.03.2018
RO21.03.2018
RS21.03.2018
SE21.03.2018
SI21.03.2018
SK21.03.2018
SM21.03.2018
BG21.06.2018
NO21.06.2018
GR22.06.2018
PT23.07.2018
LU28.08.2018
MT28.08.2018
BE31.08.2018
CH31.08.2018
LI31.08.2018
Former [2019/38]AL21.03.2018
AT21.03.2018
CY21.03.2018
CZ21.03.2018
DK21.03.2018
EE21.03.2018
FI21.03.2018
HR21.03.2018
LT21.03.2018
LV21.03.2018
MC21.03.2018
NL21.03.2018
PL21.03.2018
RO21.03.2018
RS21.03.2018
SE21.03.2018
SI21.03.2018
SK21.03.2018
SM21.03.2018
BG21.06.2018
NO21.06.2018
GR22.06.2018
PT23.07.2018
LU28.08.2018
BE31.08.2018
CH31.08.2018
LI31.08.2018
Former [2019/26]AL21.03.2018
AT21.03.2018
CY21.03.2018
CZ21.03.2018
DK21.03.2018
EE21.03.2018
FI21.03.2018
HR21.03.2018
LT21.03.2018
LV21.03.2018
MC21.03.2018
NL21.03.2018
PL21.03.2018
RO21.03.2018
RS21.03.2018
SE21.03.2018
SI21.03.2018
SK21.03.2018
SM21.03.2018
BG21.06.2018
NO21.06.2018
GR22.06.2018
PT23.07.2018
LU28.08.2018
CH31.08.2018
LI31.08.2018
Former [2019/21]AL21.03.2018
AT21.03.2018
CY21.03.2018
CZ21.03.2018
DK21.03.2018
EE21.03.2018
FI21.03.2018
HR21.03.2018
LT21.03.2018
LV21.03.2018
MC21.03.2018
NL21.03.2018
PL21.03.2018
RO21.03.2018
RS21.03.2018
SE21.03.2018
SK21.03.2018
SM21.03.2018
BG21.06.2018
NO21.06.2018
GR22.06.2018
PT23.07.2018
LU28.08.2018
CH31.08.2018
LI31.08.2018
Former [2019/15]AL21.03.2018
AT21.03.2018
CY21.03.2018
CZ21.03.2018
DK21.03.2018
EE21.03.2018
FI21.03.2018
HR21.03.2018
LT21.03.2018
LV21.03.2018
MC21.03.2018
NL21.03.2018
PL21.03.2018
RO21.03.2018
RS21.03.2018
SE21.03.2018
SK21.03.2018
SM21.03.2018
BG21.06.2018
NO21.06.2018
GR22.06.2018
PT23.07.2018
Former [2019/08]AL21.03.2018
AT21.03.2018
CY21.03.2018
CZ21.03.2018
DK21.03.2018
EE21.03.2018
FI21.03.2018
HR21.03.2018
LT21.03.2018
LV21.03.2018
NL21.03.2018
PL21.03.2018
RO21.03.2018
RS21.03.2018
SE21.03.2018
SK21.03.2018
SM21.03.2018
BG21.06.2018
NO21.06.2018
GR22.06.2018
PT23.07.2018
Former [2019/03]AL21.03.2018
AT21.03.2018
CY21.03.2018
CZ21.03.2018
EE21.03.2018
FI21.03.2018
HR21.03.2018
LT21.03.2018
LV21.03.2018
NL21.03.2018
PL21.03.2018
RO21.03.2018
RS21.03.2018
SE21.03.2018
SK21.03.2018
SM21.03.2018
BG21.06.2018
NO21.06.2018
GR22.06.2018
PT23.07.2018
Former [2018/52]AL21.03.2018
AT21.03.2018
CY21.03.2018
CZ21.03.2018
EE21.03.2018
FI21.03.2018
HR21.03.2018
LT21.03.2018
LV21.03.2018
NL21.03.2018
PL21.03.2018
RO21.03.2018
RS21.03.2018
SE21.03.2018
SK21.03.2018
SM21.03.2018
BG21.06.2018
NO21.06.2018
GR22.06.2018
Former [2018/50]AL21.03.2018
AT21.03.2018
CY21.03.2018
CZ21.03.2018
EE21.03.2018
FI21.03.2018
HR21.03.2018
LT21.03.2018
LV21.03.2018
NL21.03.2018
PL21.03.2018
RO21.03.2018
RS21.03.2018
SE21.03.2018
SK21.03.2018
BG21.06.2018
NO21.06.2018
GR22.06.2018
Former [2018/46]AL21.03.2018
CY21.03.2018
FI21.03.2018
HR21.03.2018
LT21.03.2018
LV21.03.2018
NL21.03.2018
RS21.03.2018
SE21.03.2018
BG21.06.2018
NO21.06.2018
GR22.06.2018
Former [2018/45]CY21.03.2018
FI21.03.2018
HR21.03.2018
LT21.03.2018
LV21.03.2018
NL21.03.2018
RS21.03.2018
SE21.03.2018
BG21.06.2018
NO21.06.2018
GR22.06.2018
Former [2018/40]CY21.03.2018
FI21.03.2018
HR21.03.2018
LT21.03.2018
LV21.03.2018
RS21.03.2018
SE21.03.2018
BG21.06.2018
NO21.06.2018
GR22.06.2018
Former [2018/37]CY21.03.2018
FI21.03.2018
HR21.03.2018
LT21.03.2018
NO21.06.2018
GR22.06.2018
Former [2018/35]CY21.03.2018
FI21.03.2018
HR21.03.2018
LT21.03.2018
NO21.06.2018
Cited inInternational search[YD]WO2008073687  (IRM LLC, et al) [YD] 1-21 * pages 17-18, paragraph [0040] * * claims 1, , 6, 11, 17-20 * * compounds 66, 231 *;
 [YD]WO2010020675  (NOVARTIS AG [CH], et al) [YD] 1-21 * page 11, paragraph 4 * * page 19, paragraph l - page 20, paragraph 1 * * page 21, paragraph 2 - page 22, paragraph 3 * * page 27, paragraph 2 * * page 45, paragraph 3 - page 46, paragraph 3 * * page 178; example 74 * * claims 1, 13 *;
 [Y]WO2012106540  (IRM LLC [US], et al) [Y] 1,2,4-21 * page 1, paragraph [0004] * * page 2, paragraph [0007]; compound 1 * * claims 1, 6 *;
 [XY]  - P. BONVINI ET AL, "The effect of the cyclin-dependent kinase inhibitor flavopiridol on anaplastic large cell lymphoma cells and relationship with NPM-ALK kinase expression and activity", HAEMATOLOGICA, (20090616), vol. 94, no. 7, doi:10.3324/haematol.2008.004861, ISSN 0390-6078, pages 944 - 955, XP055144707 [X] 1,4,5,8-14,16,19-21 * abstract * * page 945, column 1, paragraph 2 * * figure 5 * * page 952, column 2, paragraph 2 - page 953, column 2, paragraph 1 * * page 954, column 1, paragraph 2 - column 2, paragraph 1 * [Y] 1-21

DOI:   http://dx.doi.org/10.3324/haematol.2008.004861
 [Y]  - THOMAS H. MARSILJE ET AL, "Synthesis, Structure-Activity Relationships, and in Vivo Efficacy of the Novel Potent and Selective Anaplastic Lymphoma Kinase (ALK) Inhibitor 5-Chloro- N 2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)- N 4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine (LDK378) Currently in Phase 1 and Pha", JOURNAL OF MEDICINAL CHEMISTRY, (20130725), vol. 56, no. 14, doi:10.1021/jm400402q, ISSN 0022-2623, pages 5675 - 5690, XP055145299 [Y] 1,2,4-21 * abstract * * page 5675, column 1, paragraph 2 - column 2, paragraph 2 * * figure 1 * * table 4 * * page 5681, column 1, paragraph 1 * * page 5682, column 2, paragraph 1 - page 5683, column 1, paragraph 1 *

DOI:   http://dx.doi.org/10.1021/jm400402q
 [Y]  - ROBERT ROSKOSKI, "Anaplastic lymphoma kinase (ALK): Structure, oncogenic activation, and pharmacological inhibition", PHARMACOLOGICAL RESEARCH, (20130201), vol. 68, no. 1, doi:10.1016/j.phrs.2012.11.007, ISSN 1043-6618, pages 68 - 94, XP055145296 [Y] 11-18 * abstract * * page 76, column 2, paragraph 3 * * tables 3, 4 * * page 77, column 2, paragraph 2 * * page 78, column 1, paragraph 4 * * page 81, column 1, paragraph 2 * * page 82, column 2, paragraph 1 - page 83, column 1, paragraph 2 * * figure 7 * * page 87, column 2, paragraph 2 *

DOI:   http://dx.doi.org/10.1016/j.phrs.2012.11.007
 [YP]  - BENGT HALLBERG ET AL, "Mechanistic insight into ALK receptor tyrosine kinase in human cancer biology", NATURE REVIEWS CANCER, (20130924), vol. 13, no. 10, doi:10.1038/nrc3580, ISSN 1474-175X, pages 685 - 700, XP055086717 [YP] 1-21 * abstract * * Key points; page 688, column 1, paragraph 1 * * figure 1 * * page 695, column 1, paragraph 2 * * page 696, column 1, paragraph 2 * * page 696, column 2, paragraph 4 *

DOI:   http://dx.doi.org/10.1038/nrc3580
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.